TABLE 4.
Clinical trials of CELMoDs in tumors.
| Drug | Alias | NCT number | Phase | Conditions | Interventions |
|---|---|---|---|---|---|
| CC-122 | Avadomide | NCT02509039 | 1 | NHL, Solid Tumors | CC-122 |
| NCT02859324 | 1, 2 | Unresectable HCC | CC-122, Nivolumab | ||
| NCT02323906 | 1 | HCC | CC-122, Sorafenib | ||
| NCT03834623 | 2 | Advanced Melanoma | CC-122, Nivolumab | ||
| NCT02031419 | 1 | DLBCL, FL | CC-122, CC-223, Rituximab, CC-292 | ||
| NCT02417285 | 1 | Relapsed/Refractory DLBCL, iNHL | Obinutuzumab, CC-122 | ||
| NCT02406742 | 1,2 | CLL, SLL | CC-122, Ibrutinib, Obinutuzumab | ||
| NCT03283202 | 1 | DLBCL | CC-122, R-CHOP | ||
| NCT01421524 | 1 | NHL, Solid Tumors, MM | CC-122 | ||
| CC-220 | Iberdomide | NCT04882163 | 1, 2 | B-cell Lymphoma | CC-220, Polatuzumab vedotin, Rituximab, Tafasitamab, Gem, DDP, DEX, Bendamustine, Len |
| NCT03161483 | 2 | SLE | CC-220, Placebo | ||
| NCT02185040 | 2 | SLE | CC-220, Placebo | ||
| NCT04884035 | 1 | a-BCL | CC-220, R-CHOP, CC-99282 | ||
| NCT04464798 | 1 | RR Lymphoma | CC-220, Rituximab, Obinutuzumab | ||
| NCT02773030 | 1, 2 | MM | CC-220, DEX, DARA, BTZ, CFZ | ||
| NCT02192489 | 2 | Skin Sarcoidosis | CC-220, Placebo | ||
| NCT04564703 | 2 | MM | CC-220 | ||
| NCT04392037 | 2 | MM | CC-220, cyclophosphamide, DEX | ||
| NCT04855136 | 1, 2 | MM | BB2121, CC-220, BMS-986405, Pom, DEX, BTZ | ||
| NCT03310619 | 1, 2 | NHL, DLBCL, FL | JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282 | ||
| CC-92480 | — | NCT03989414 | 1, 2 | MM | CC-92480, BTZ, DEX, DARA, CFZ, Elotuzumab, Isatuximab |
| NCT03374085 | 1, 2 | MM | CC-92480, DEX |
Abbreviation: NHL, Non-Hodgkin’s lymphoma; HCC, hepatocellular carcinoma; DBLCL, Diffuse large B-cell lymphoma; iNHL, indolent NHL; CLL, Chronic lymphocytic leukemia; FL, Follicular lymphoma; MM, multiple myeloma; BCL, B-cell Lymphoma; SLE, systemic lupus erythematosus; RR, Lymphoma, relapsed/refractory lymphoma; R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone); DEX, dexamethasone; DARA, daratumumab; BTZ, bortezomib; CFZ, carfilzomib; Len, Lenalidomide; Gem, gemcitabine; DDP, Cisplatin; Pom, Pomalidomide.